Clinical trial
AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
NCT00768339 is registered in ClinicalTrials.gov with Aegera Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
- Lead sponsor
- Aegera Therapeutics
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 30, 2008
- Completion date
- September 30, 2011
- Enrollment
- 25 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.